DexCom, Inc. (NASDAQ:DXCM) Receives $104.59 Consensus Price Target from Analysts

DexCom, Inc. (NASDAQ:DXCM) has been assigned a consensus rating of “Moderate Buy” from the eighteen ratings firms that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $104.59.

A number of equities research analysts have commented on DXCM shares. Morgan Stanley lowered their target price on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Leerink Partners cut their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Barclays decreased their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. Finally, Raymond James cut their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th.

DexCom Price Performance

DexCom stock opened at $74.48 on Tuesday. The firm has a market capitalization of $29.09 billion, a PE ratio of 45.05, a P/E/G ratio of 2.30 and a beta of 1.17. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The firm’s 50-day simple moving average is $70.43 and its 200 day simple moving average is $90.34. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Orion Portfolio Solutions LLC boosted its holdings in DexCom by 31.9% in the first quarter. Orion Portfolio Solutions LLC now owns 9,871 shares of the medical device company’s stock valued at $1,369,000 after purchasing an additional 2,388 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of DexCom by 40.3% during the first quarter. Acadian Asset Management LLC now owns 8,008 shares of the medical device company’s stock worth $1,109,000 after buying an additional 2,299 shares in the last quarter. O Shaughnessy Asset Management LLC increased its stake in shares of DexCom by 25.5% in the first quarter. O Shaughnessy Asset Management LLC now owns 22,027 shares of the medical device company’s stock worth $3,055,000 after buying an additional 4,481 shares during the last quarter. Clearbridge Investments LLC raised its holdings in DexCom by 29.8% in the first quarter. Clearbridge Investments LLC now owns 38,958 shares of the medical device company’s stock valued at $5,403,000 after acquiring an additional 8,936 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its stake in DexCom by 3.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 298,413 shares of the medical device company’s stock valued at $41,432,000 after acquiring an additional 9,662 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.